From clones to claims: the European Patent Office's case law on the patentability of biotechnology inventions in comparison to the United States and Japanese practice
Gespeichert in:
Format: | Buch |
---|---|
Sprache: | English |
Veröffentlicht: |
Köln ; München [u.a.]
Heymann
2012
|
Ausgabe: | 5. ed. |
Schriftenreihe: | Heymanns intellectual property
|
Schlagworte: | |
Online-Zugang: | Inhaltsverzeichnis |
Beschreibung: | XXX, 1240 S. |
ISBN: | 9783452274328 |
Internformat
MARC
LEADER | 00000nam a2200000 c 4500 | ||
---|---|---|---|
001 | BV036724657 | ||
003 | DE-604 | ||
005 | 20160217 | ||
007 | t | ||
008 | 101018s2012 |||| 00||| eng d | ||
020 | |a 9783452274328 |9 978-3-452-27432-8 | ||
035 | |a (OCoLC)705908651 | ||
035 | |a (DE-599)BVBBV036724657 | ||
040 | |a DE-604 |b ger |e rakwb | ||
041 | 0 | |a eng | |
049 | |a DE-703 |a DE-M382 |a DE-19 |a DE-12 | ||
084 | |a PE 715 |0 (DE-625)135539: |2 rvk | ||
084 | |a PS 3800 |0 (DE-625)139790: |2 rvk | ||
245 | 1 | 0 | |a From clones to claims |b the European Patent Office's case law on the patentability of biotechnology inventions in comparison to the United States and Japanese practice |c by Hans-Rainer Jaenichen ... |
250 | |a 5. ed. | ||
264 | 1 | |a Köln ; München [u.a.] |b Heymann |c 2012 | |
300 | |a XXX, 1240 S. | ||
336 | |b txt |2 rdacontent | ||
337 | |b n |2 rdamedia | ||
338 | |b nc |2 rdacarrier | ||
490 | 0 | |a Heymanns intellectual property | |
610 | 2 | 7 | |a Europäisches Patentamt |0 (DE-588)1052705-9 |2 gnd |9 rswk-swf |
650 | 0 | 7 | |a Biotechnologie |0 (DE-588)4069491-4 |2 gnd |9 rswk-swf |
655 | 7 | |0 (DE-588)4152408-1 |a Entscheidungssammlung |2 gnd-content | |
689 | 0 | 0 | |a Europäisches Patentamt |0 (DE-588)1052705-9 |D b |
689 | 0 | 1 | |a Biotechnologie |0 (DE-588)4069491-4 |D s |
689 | 0 | |5 DE-604 | |
700 | 1 | |a Jaenichen, Hans-Rainer |e Sonstige |0 (DE-588)1030592500 |4 oth | |
856 | 4 | 2 | |m SWB Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=020642454&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
999 | |a oai:aleph.bib-bvb.de:BVB01-020642454 |
Datensatz im Suchindex
_version_ | 1804143374661320704 |
---|---|
adam_text | IMAGE 1
CONTENTS
FOREWORD V
PREFACE VII
CONTRIBUTORS TO THE FIFTH EDITION XIII
CONTENTS - SUMMARY XV
INTRODUCTION TO THE 5TH EDITION 1
1 PATENTABLE SUBJECT MATTER/INDUSTRIAL APPLICABILITY/UTILITY: LEGAL
BASIS, SUMMARY AND DISCUSSION OF THE EPO, US AND JPO PRACTICE 6
1.1 PATENTABLE SUBJECT MATTER/INDUSTRIAL APPLICABILITY: EPO (ARTICLES 52
AND 53 EPC1973, ARTICLES 52, 53 AND 54(5) EPC2000, THE EU DIRECTIVE
98/44/EC OF JULY 6, 1998 AND ITS IMPLEMENTATION BY THE EPO) 6
1.2 PATENTABLE SUBJECT MATTER/UTILITY: US (35 U. S. C. § 101 (1984)) 20
1.3 PATENTABLE SUBJECT MATTER/INDUSTRIAL APPLICABILITY: JPO 32
2 PATENTABLE SUBJECT MATTER: THE EPO S CASE LAW 39
2.1 THE EXCLUSION OF PLANT AND ANIMAL VARIETIES AND THE EXCLUSION OF
STEM CELL INVENTIONS FROM PATENT PROTECTION IN CONSIDERATION OF ARTICLE
53 EPC 39 2.2 THE EXCLUSION OF ESSENTIALLY BIOLOGICAL PROCESSES FOR THE
PRODUCTION OF PLANTS FROM PATENT PROTECTION: T 320/87, HYBRID
PLANTS/LUBRIZOL, EP-A 4 723, OJ
EPO 1990, 71, T 83/05, BROCCOLI/PLANT BIOSCIENCE, EP-B1 1 069 819 53
2.3 THE EXCLUSION OF ESSENTIALLY BIOLOGICAL PROCESSES FOR THE
PRODUCTION OF ANIMALS FROM PATENT PROTECTION: T 19/90,
ONCO-MOUSE/HARVARD, EP-A 169 672, OJ EPO 1990,476 57
2.4 THE PATENTING OF HUMAN DNA IS NOT INTRINSICALY UNETHICAL 57
2.5 COMPOUNDS AND DISCOVERIES, INDUSTRIAL APPLICABILITY 59
2.6 THE PATENTING OF PHARMACEUTICAL INVENTIONS 70
2.7 THE PATENTING OF DIAGNOSTIC INVENTIONS AND SCREENING METHODS 77
3 THE PERSON SKILLED IN THE ART: LEGAL BASIS, SUMMARY AND DISCUSSION OF
THE EPO, US AND JPO PRACTICE 78
3.1 THE PERSON SKILLED IN THE ART: EPO 78
3.2 THE PERSON SKILLED IN THE ART: US 79
3.3 THE PERSON SKILLED IN THE ART: JPO 81
4 THE PERSON SKILLED IN THE ART: THE EPO S CASE LAW 83
5 CORRECTIONS AND AMENDMENTS: LEGAL BASIS, SUMMARY AND DISCUSSION OF THE
EPO, US AND JPO PRACTICE 86
5.1 CORRECTIONS AND AMENDMENTS: EPO (ARTICLE 123 AND RULE 88
EPC1973/RULE 139 EPC2000) 86
5.2 CORRECTIONS AND AMENDMENTS US 91
5.3 CORRECTIONS AND AMENDMENTS: JPO 96
6 CORRECTIONS AND AMENDMENTS: THE EPO S CASE LAW 102
6.1 T184/91, KGLU-GLN/CELTRK*, EP-A 169 016, G11/91, GLU-GLN/CELTRIX,
XIX
IMAGE 2
CONTENTS
EP-A 169 016; AND T 1147/98, CARTILAGE-INDUCING FACTOR/CELTRIX
PHARMACEUTICALS INC., EP-B1 169 016 102
6.2 T 161/86, AMINO ACID SEQUENCE MODIFICATION/ELI LILLY, EP-A 10 421
. .. 103 6.3 T 552/91, CHROMAN DERIVATIVES/MERCK, EP-A 273 262 104
6.4 T 21/86, AMENDMENTS/AMERICAN MONITOR CORP., EP-A 9 222 105 6.5 T
365/88 IMPROVED VECTORS/BIOGEN, EP-A 41 767 106
6.6 T 449/90, ..TREATMENT OF PLASMA/CEDARS-SINAI, EP-B 94 611 106
6.7 T 157/90, HUMAN CALCITONIN STRUCTURAL GENE/CELLTECH, EP-A 70 675 .
.. 107 6.8 T 923/92, T-PA/GENENTECH, EP-B1 93 619, OJ EPO 1996, 564
108
6.9 T 749/94, ERYTHROPOIETIN/GENETICS INSTITUTE*, EP-B1 209 539 I LL
6.10 T 379/95, HORMONES/ARS, EP-B1 160 699 112
6.11 T 1046/96, PERTUSSIS/LELAND STANFORD , EP-B 1275 689 113
6.12 T 277/95, PRODUCTION OF ERYTHROPOIETIN/GENETICS INSTITUTE , EP-B1
411 678 114
6.13 T 656/94, ..COLONY-STIMULATING FACTOR/KIRIN-AMGEN, EP-B1 237 545 .
.. 114 6.14 T 824/94, ..LAV/INSTITUT PASTEUR, EP-B1 178 978 115
6.15 T 138/95, INTRAPULMONARY DELIVERY/GENENTECH INC., EP-B1 257 956 .
116 6.16 T 985/95, ..TREATMENT OF INFERTILITY/NOVO NORDISK A/S, EP-B1
300 021 116 6.17 T 289/97, BRASSICA/CALGENE, EP-B1 270 615 117
6.18 T 354/97, ..PROTEIN SECRETION/GENENTECH, EP-B1 88 632 118
6.19 T 658/98, INTERFERON-BETA 2A/YEDA RESEARCH , EP-A 645 542 119
6.20 T 588/95, ..CHIMERA MONOCLONAL ANTIBODY/RESEARCH DEVELOPMENT ,
EP-B1 171 496 119
6.21 T 188/97, NANBV/CHIRON CORPORATION , EP-B1 318 216 120
6.22 T 1054/97, ..INSECT CONTROL/AVENTIS, EP-B1 451 878 121
6.23 T 32/97, ..DELETED TK-PRV VACCINES/NOVAGENE, EP-B1 149 040 122
6.24 T 339/98, ..VITAMIN K-DEPENDENTPROTEINS/ELI LILLY , EP-B1 363 126
122 6.25 T 725/99, ..LIVE VACCINES/LELAND STANFORD JUNIOR UNIVERSITY ,
EP-B1 184 086 123
6.26 T 351/98, ..HIV-I/CHIRON CORPORATION , EP-B1 181 150 124
6.27 T 239/95, ..HERPES SIMPLEX VIRAL PROTEINS/AMERICAN CYANAMID CO.,
EP-B1 101 655 125
6.28 T 4 5 0 / 9 8, BPI FRAGMENTS/NEW YORK UNIVERSITY , EP-B1 375 724 .
.. 125 6.29 T 93/98, TNF INHIBITING PROTEIN/BASF, EP-B1 471 701 126
6.30 T 1118/98, ..NUCLEIC ACIDS/DU PONT DE NEMOURS, EP-B1 520 039 . ..
126 6.31 T 160/99, ..CHLAMYDIA/WASHINGTON, EP-B 1264 434 127
6.32 T 232/99, PROTEIN PRODUCTION/ALUSUISSE HOLDINGS A. G., EP-B1 239
292 . 127
6.33 T 756/00, ..IMMUNOTHERAPY/CENTOCOR INC., EP-A 755 683 128
6.34 T 346/01, ..OSTEOPOROSIS/NOVARTIS , EP-A 560 723 128
6.35 T 216/96, ..PROCESS FOR AMPLIFYING, DETECTING AND/OR CLONING
NUCLEIC ACID SE- QUENCES/F. HOFFMANN-LA ROCHE AG, EP-B1 200 362 128
6.36 T 785/97, SUPPORT-BOUND OLIGONUCLEOTIDES/OXFORD GENE TECHNOL- OGY
LIMITED , EP-B1 386 229 129
6.37 T 310/99, DOWN SYNDROME/MACRI, EP-B1 409 956 129
6.38 T 944/99, PESTICIDAL TOXINS/MYCOGEN CORPORATION , EP-B1 340 948
130 6.39 T 279/00, ..ASYMMETRIC REDUCTION PROCESS/AVECIA LTD., EP-B 1
658 211 .. 131 6.40 T 502/00, ..DETERMINATION OF AN ANALYTE/DADE, EP-B1
492 499 131
6.41 T 608/00, ..TRANSGENIC BOVINE/PHARMING, EP-B1 502 976 131
6.42 T 748/00, OLIGOMER LIBRARIES/AFFYMAX, EP-B1 604 552 132
6.43 T 1000/00, ..TEST DEVICE/ROCHE, EP-B1 654 659 132
6.44 T 1228/01, ZONA PELUCIDA ANTIGENS/ZONAGEN INC., EP-A 396 552 133
6.45 T 86/01, ..ENGINEERED BACTERIOPHAGES/ACAMBIS, EP-B1 552 267 135
XX
IMAGE 3
CONTENTS
6.46 T 98/01, ALIERGENIC PROTEINS/IMMULOGIC PHARMACEUTICAL
CORPORATION*, EP-BL 463 059 135
6.47 T 189/01, IFN-|32/IL-6R/YEDA RESEARCH AND DEVELOPMENT CO., LTD.,
EP-BL 413 908 135
6.48 T 1133/00, TUMORSUPPRESSION/UNIVERSITYOF CALIFORNIA.., EP-BL 475
623 136
6.49 T 286/01, HUMANISED ANTIBODIES/CELLTECH THERAPEUTICS LTD., EP-BL
460 167 136
6.50 T 345/01, CELLULOSE DEGRADING ENZYME/NOVOZYMES, EP-BL 531 315 .
.. 137 6.51 T 836/01, INTERFERON-BETA2/YEDA RESEARCH AND DEVELOPMENT
CO. LTD., EP-A 835 661 137
6.52 T 882/01, PROTEIN EXPRESSION SYSTEM/CELLTECH, EP-BL 651 803 137
6.53 T 1014/01, RECOMBINANT IMMUNOCONJUGATES/BRISTOL-MYERS SQUIBB CO.,
EP-BL 439 095 138
6.54 T 1100/01, TRUNCATED TRANSMEMBRANE PACE/GENETICS, EP-BL 574 402 .
138 6.55 T 1080/01, THERMOSTABLE ENZYME/F. HOFFMANN-LA ROCHE, EP-BL
258 017 139
6.56 T 161/02, TRANSGENIC ZEA MAYS PLANTS/SYNGENTA, EP-BL 513 849 140
6.57 T 579/01, CYTOPLASMIC MALE STERILE PLANTS/ENZA ZADEN, EP-BL 771
523 . 140 6.58 T 960/02, TRANSFECTION/TRANSKARYOTIC THERAPIES, EP-BL
649 464 141 6.59 T 1067/02, CHANGED EPITOPES/NOVOZYMES, EP-BL 561 907
142
6.60 T 157/03, REDUCING BLOOD LOSS/ZYMOGENETICSS EP-BL 624 095 143 6.61
T 1050/99, CARBONYL HYDROLASES/GENENCOR, EP-BL 251 446 143
6.62 T 931/01, RIBOZYME/UNIVERSITY PATENTS.., EP-BL 291 533 144
6.63 T 877/03, ANTI-CD30 ANTIBODIES/ROCHE, EP-BL 805 871 145
6.64 T 626/00, FRAMEWORK-MUTATED ANTIBODIES/WELLCOME.., EP-BL 549 581 .
. 145 6.65 T 27/04, JAPANESE HEPATITIS C VIRUS/CHIRON, EP-BL 419 182
147
6.66 T 20/04, FLT3 LIGANDS/SCHERING, EP-BL 699 236 147
6.67 T 1331/04, MSF/GENETICS INSTITUTE.., EP-A 567 599 148
6.68 T 342/02 AND T 462/07, END-LABELED NUCLEOTIDE PROBE/ENZO, EP-BL
330 221, 148
6.69 T 464/94, ^TRANSFORMATION OF PLANT GENETIC MATERIAL/NOVARTIS,
EP-BL 164 575 149
6.70 T 506/02, MEASLES VIRUS/IMPFINSTITUT*, EP-BL 780 475 149
6.71 T 1052/02, IMMUNOCHROMATOGRAPHIC METHOD/PACIFIC BIOTECH, EP-BL
466 914 150
6.72 T 937/02, G-CSF/OSAKA BIOSCIENCE, EP-AL 521 156 150
6.73 T 1189/02, HOMOLOGOUS RECOMBINATION/CELL GENESYS, EP-BL 747 485 .
151 6.74 T 243/03, PLANT PATHOGENS/MOGEN, EP-BL 474 857 152
6.75 T 494/03, TRANSGENIC WHEAT/SYNGENTA, EP-BL 674 715 152
6.76 T 79/04, PRION PROTEINS/PROTEUS, EP-BL 616 613 153
6.77 T 94/04, CYTOKINE ANTAGONISTS/REGENERON, EP-BL 726 954 153
6.78 T 168/04, YEAST VECTOR/YOCUM, EP-BL 707 068 154
6.79 T 329/04, ABSORPTION OF MINERALS/NESTLE, EP-BL 1 003 532 154
6.80 T 491 /04, ANTI TNF-A ANTIBODY/PHARMACIA & UPJOHN, EP-B1 492 448
155 6.81 T 500/01, HUMANIZED IRNMUNOGLOBULINS/PROTEIN DESIGN LABS, I N
C ., EP-BL 451 216 155
6.82 T 21/05, CTL RESPONSES TO HCV/SCRIPPS, EP-BL 759 937 157
6.83 T 35/05, TNF LIGANDS/YEDA, EP-BL 585 939 157
6.84 T 59/05 GALACTOPYRANOSIDES/PROCUR, EP-AL 873 414 158
6.85 T 248/05, PARTICUIATE DIRECT KBEL/INVERNESS, EP-BL 560 411 159
6.86 T 313/05, APPARATUS FOR MONITORING APOLYMERASE CHAIN
REACTION/APPLERA, EP-BL 872 562 159
XXI
IMAGE 4
CONTENTS
6.87 T 634/05, ..FACTOR VIII:C/NOVARTIS, EP-B1 466 199 161
6.88 T 1470/05, HCVT-CELL EPITOPES/INNOGENETICS, EP-BL 725 824 . . ..
161 6.89 T 1491/05, GENE EXPRESSION/CSIRO, EP-A1 1 071 762 162
6.90 T 1181/06, POLYKETIDES/STANFORD, EP-B1 725 778 162
6.91 T25/06, BOTULINUMTOXIN/SOLSTICENEUROSCIENCES,EP-BL 1 112 082 163
6.92 T 1188/06, MOLECULAR EVOLUTION/BIOINVENT, EP-B1 988 378 163 6.93
T 1497/06, GPCR/ARENA, EP-A1 1 580 271 164
6.94 T 1213/05, ..BREAST AND OVARIAN CANCER/UNIVERSITY OF UTAH, EP-B1
705 902 164
6.95 T 1048/05, LUCIFERASE/PERKIN ELMER LAS, EP-B1 610 937 167 6.96 T
582/06, DNA MUTAGENESIS/MAXYGEN, EP-B1 752 008 167
6.97 T 1099/06, ..TRANSGENIC PLANT CELLS/MAX PLANCK, EP-B1 290 799 168
6.98 T 411/02, CTLA4 RECEPTOR/BRISTOL-MYERS SQUIBB, EP-B1 606 217 .
168 6.99 T 580/05, ..HUMANISED ANTIBODIES/CELLTECH, EP-B1 626 390 169
6.100 T 542/04, SOYBEAN PRODUCTS/E. I. DU PONT DE NEMOURS, EP-B1 608359
170
6.101 T 1443/04, ..REGENERATION OF GRAMINEAE PLANTS/SYNGENTA, EP-B1 332
581 171 6.102 T 725/05, ..HUMANIZED IMMUNOGLOBULINS II/PDL, EP-BL 682
040 171 6.103 T 795/06, BOTULINUM NEUROTOXINE/MERZ, EP-B1 1 185 291
171
6.104 T 329/06, ..PERFUSED MICROTISSUE/MIT, EP-B1 1 064 353 172
6.105 T 405/06, IMMUNOGLOBULINS/BRUSSEL, EP-B1 656 946 172
6.106 T 801 /06, ..CANCER TREATMENT WITH HSV MUTANT/CRUSADE, EP-B1 773
785 173 6.107 T 997/06, ..INSULIN PREPARATION/NOVO NORDISK, EP-B1 921
812 174 6.108 T 1107/06, ..BOTULINUM TOXINS/ALLERGAN, EP-B1 1 005 867
174
6.109 T 1408/06, VEGF-RELATED PROTEIN/GENENTECH, EP-B1 848 755 175
6.110 T 1772/06, ..CLARITHROMYCIN/ABBOTT, EP-B1 915 899 176
6.111 T 1790/06, ..EXPRESSION OF A GENE/ALNYLAM (DECEMBER 9,2008),
EP-B1 1 144 623 176
6.112 T 382/07, ..ETHERIC OILS/D&W TRADING, EP-B1 828 502 176
6.113 T 391/07, ..IMMUNOTHERAPY OF CANCER/UNIVERSITY OF PENNSYLVANIA*,
EP-B1 790 835 177
6.114 T 1898/07, ..INTERFERON FORMULATIONS/BIOGEN, EP-B1 948 358 178
6.115 T 617/07, ..MONOCLONAL NGF-ANTAGONIST ANTIBODIES/LAY LINE, EP-BL
1 181 318 179
6.116 T 665/07, ..HETEROLOGOUS GENES/EDINBURGH, EP-BL 695 361 180 6.117
T 762/07, ..ESTROGEN RECEPTOR/ORGANON, EP-BL 798 378 180
6.118 T 837/07, ..DIAGNOSTIC PRIMERS/INFECTIO, EP-BL 804 616 181
6.119 T 1068/07, ..ENZYMATIC DNA/SCRIPPS, EP-A1 981 646 181
6.120 T 1128/07, HIV-2 VARIANTS/QUIAGEN, EP-BL 655 501 183
6.121 T 1331 /07, ..COLLAGEN-LIKE POLYMERS/PROTEIN POLYMER*, EP-BL 670
848 183 6.122 T 1437/07, BOTULINUM TOXIN FOR TREATING SMOOTH MUSCLE
SPASM/ALLERGAN, EP-BL 1 010 431 184
6.123 T 1885/07, ..ALPHAVIRUS VECTORS/BIOPTION, EP-BL 753 053 184
6.124 T 1/08, ALPHAVIRUSES/BIOPTION, EP-BL 561 890 184
6.125 T 692/08, ..LAWSONIA INTRACELLULARIS/BOEHRINGER, EP-BL 843 818
185 6.126 T 1022/08, ..TRIFUNCTIONAL REAGENT/MITRA, EP-A1 1 569 690 185
6.127 T 1477/08, ..ACE INHIBITORS/SANOFI-AVENTIS*, EP-BL 1 212 081 186
6.128 T 2351/08, HSP70 PROTEIN/MULTHOFF, EP-BL 1 066 050: RECORDING OF
ORAL PROCEEDINGS BY A PARTY 186
6.129 T 1001/07, OINTMENT/KAPAJ, EP-AI 1 532 982 187
6.130 T 1644/08, .ENDOGLUCANASES/NOVOZYMES, EP-BL 815 209 187 6.131 T
445/09, ..TREATMENT OF AUTOIMMUNE DISEASES/GENENTECH, EP-BL 1 176 981
188
6.132 T 783/09, ANTIDIABETIC COMBINATIONS/NOVARTIS, EP-BL 1 248 604
188
XXII
IMAGE 5
CONTENTS
6.133 T 878/09, METHOD FOR THE DETECTION OF PRION PROTEINS/PROTHERICS,
EP-BL 616 613 189
6.134 T 1271/09, EXPRESSION OF A GENE/ALNYLAM, EP-BL 1 214 945 189
6.135 T 244/10, DIAGNOSIS AUTOIMMUNE/DIAGNOSTIC HYBRIDS , EP-A1 1 268
846 189
6.136 T 305/07, TRISULFIDES/PFIZER, EP-BL 1 095 055 190
6.137 T 1456/06, TELOMERASE/GERON, EP-BL 841 396 190
6.138 T 1172/08, METHOD FOR DETERMINING T-CELL EPITOPES/GENENCOR,
EP-BL 1 073 754 191
6.139 T 76/09, PROTEIN FRAGMENT COMPLEMENTATION ASSAY/ODYSSEY, EP-A1 1
305 627 192
6.140 T 341/09, ANTIBODY/WELLCOME, EP-BL 1 247 865; 193
6.141 T 583/09, NOVEL GENES/MILLENIUM, EP-A1 1 194 534 193
6.142 T 1803/09, -MARKERS CONGESTIVE HEART FAILURE/SYN.X PHARMA, EP-A1
1 423 705 194
6.143 T 191/08, HAEMAGGLUTININ MOLECULE COMPLEX/NOVARTIS, EP-BL 589
348 . 195
7 CLARITY OF CLAIMS: LEGAL BASIS, SUMMARY AND DISCUSSION OF THE EPO, US
AND JPO PRACTICE 196
7.1 CLARITY OF CLAIMS: EPO (ARTICLE 84 EPC) 196
7.2 CLARITY OF CLAIMS: US 199
7.3 CLARITY OF CLAIMS: JPO 202
8 CLARITY OF CLAIMS: THE EPO S CASE LAW 204
8.1 T 301/87, ALPHA-INTERFERONS/BIOGEN, EP-B 32 134, OJ EPO 1990, 335
TO 358 204
8.2 T 281/86, PREPROTHAUMATIN/UNILEVER, EP-A 54 331, OJ EPO 1989, 202
TO 209 205
8.3 T 181 /87, DNA TRANSFER VECTOR/THE REGENTS OF THE UNIVERSITY OF
CALIFORNIA.., EP-A 20 251 206
8.4 T 269/87, PROCHYMOSIN/CELLTECH, EP-A 68 691 207
8.5 T 347/87, METHOD OF CONSTRUCTING A REPLICABLE CLONING
VEHICLE/GENENTECH, EP-A 22 242 207
8.6 T 130/90 ) RECOMBINANT MONOCLONAL AIITIBODY/UNIVERSITY OF TEXAS
SYSTEM.., EP-B 68 763 208
8.7 T 391 /91, ICE NUDEATING/UNIVERSITY OF CALIFORNIA*, EP-A 112 342
209 8.8 T 430/92, ..GROWTH OF TULIPS/SUMITOMO, EP-BL 188 933 210
8.9 T 749/94, ERYTHROPOIETIN/GENETICS INSTITUTE*, EP-BL 209 539 211
8.10 T 464/94, TRANSFORMATION OF PLANT GENETIC MATERIAL/NOVARTIS,
EP-BL 164 575 211
8.11 T 250/96, TRANSFBRMATION/NOVARTIS, EP-A1 429 093 212
8.12 T 277/95, PRODUCTION OF ERYTHROPOICTIN/GENETICS INSTITUTE*, EP-BL
411 678 213
8.13 T 484/98, MODIFIED YEAST/ELSWORTH, EP-A 463 024 213
8.14 T 965/98, DNA AMPLIFICATION/HOFFMANN-LA ROCHE, EP-A 509 612 . 214
8.15 T 966/98, DNA DETECTION/HOFFMANN-LA ROCHE.., EP-A 502 589 215 8.16
T 188/97, NANBV/CHIRON CORPORATION*, EP-BL 318 216 215
8.17 ^SEROTONIN RECEPTOR/ELI LILLY, EP-A 449 562, OJ EPO 2001, 103 215
8.18 T 1044/99, IONOPHORE ANTIBIOTICS/UNGDA, EP- 615 544 216
8.19 T 680/98, IMPROVED VECTORS H/BIOGEN, EP-BL 41 767 216
8.20 T 822/98, PROBES/BIO-RAD, EP-BL 246 864 217
XXIII
IMAGE 6
CONTENTS
8.21 T 239/95, HERPES SIMPLEX VIRAL PROTEINS/AMERICAN CYANAMID CO.,
EP-B1 101 655 218
8.22 T 64/00, INSECTICIDAL PLANT EXPRESSION/MYCOGEN, EP-B1 359 472 218
8.23 T 984/00, TI-PLASMID VECTORS/MAX-PLANCK-GESELLSCHAFT, EP-A 290
799 219
8.24 T 1084/00, HIV-3 VARIANTS/INNOGENETICS, EP-A1 657 532 220
8.25 T 397/02, .ENDOGENOUS GENE EXPRESSION/APPLIED RESEARCH SYS, EP-B
505 500 221
8.26 T 2 8 5 / 0 1, BONE RESORPTION/WASHINGTON RESEARCH FOUNDATION*,
EP-B1 394 296 221
8.27 T 6 1 0 / 0 1, ..PLANT GROWTH/LONG AS H T ON RESEARCH STATION,
EP-A 703 983 222
8.28 T 347/02, ..NEOPLASTIC PHENOTYPE/UNIVERSITY OF CALIFORNIA.., EP-B1
440 744 222
8.29 T 1074/00, HEMATOPOIETIC GROWTH FACTORS/GENETICS INSTITUTE*, EP-B1
314 705 222
8.30 T 378/02, ..ANALYSIS OF POLYNUCLEOTIDE SEQUENCES/OXFORD GENE
TECHNOLOGY.., EP-B1 373 203 224
8.31 T 1146/02, VACCINES CONTAINING A SAPONIN AND A STEROL/SMITHKLINE
BEECHAM.., EP-B1 822 831 225
8.32 T 741 / 0 3, ..TREATMENT OF DIABETES/LONDON HEALTH SCIENCES.., EP-B
1 762 890 225
8.33 T 748/04, BIOACTIVE FACTORS OF ALOE VERA PLANTS/CARRINGTON, EP-A1
871 460 225
8.34 T 843/04, ..GAS DRIVEN FERMENTATION/PRAXAIR.., EP-B1 829 534 226
8.35 T 1326/04, AVIAN ADENOVIRUS VECTOR/COMMONWEALTH CSIRO, EP-A1 690
612 227
8.36 T 2 9 / 0 5, ..PVA/BRISTOL-MYERS, EP-A1 718 402 228
8.37 T 710/05, NMDA OXIDIZING AGENTS/THE CHILDREN S MEDICAL CEN- TER..,
EP-A1 486 621 229
8.38 T 723/05, ..GROWTH HORMONE/PHARMACIA AKTIEBOLAG, EP-B1 587 858 229
8.39 T 1060/05, ..SECURITY SYSTEM/CRIME SOLUTIONS*, EP-A1 1 230 392 . .
.. 229
8.40 T 1300/05, RET SCREENING ASSAY/PROGENICS, EP-A1 847452 230
8.41 T 25/06, ..BOTULINUM TOXIN/SOLSTICE NEUROSCIENCES, EP-B1 1 112 082
231
8.42 T 18/02, ..MUTANT ALPHA-AMYLASE/GENENCOR, EP-B1 689 589 231
8.43 T 412/06, ..PROTEINASE INHIBITOR/MAX-PLANCK-GESELLSCHAFT ZUR
FOERDERUNG.., EP-A1 1 207 876 232
8.44 T 1018/06, ..ISCHEMIA DETECTION/ISCHEMIA, EP-A1 1 411 356 232
8.45 T 1599/06, ..MYCOBACTERIUM VACCINATING AGENT/UNIVERSITY OF CALIFOR-
NIA, EP-B1 771 322 233
8.46 T 411/02, CTLA4 RECEPTOR/BRISTOL-MYERS SQUIBB, EP-B1 606 217 .
234 8.47 T 640/06, HSVPARTICLES/BIOGEN, EP-B1 1 135 408 234
8.48 T 936/06, ..BACTERIOHAGE PREPARATIONS/NYMOX, EP-A1 895 534 235
8.49 T 1815/06, PRE-LIGAND ASSOCIATION D O M A I N / T HE G O V E R N M
E NT OF T HE U N I T ED STATES, EP-A1 1 263 788 235
8.50 T 449/08, RENAL CLEARANCE/U. D. TESTING*, EP-A1 817 966 236
8.51 T 692/08, LAWSONIA INTRACELLULARIS/BOEHRINGER, EP-B1 843 818 236
8.52 T 744/08, ..RECOVERY OF VIRUS/XENOVA, EP-B1 1 002 055 237
8.53 T 1423/08, ..MEDIUM SUPPLEMENT/LIFE TECHNOLOGIES*, EP-986 635 ..
237 8.54 T 1644/08, ENDOGLUCANASES/NOVOZYMES, EP-B1 815 209 238
8.55 T 878 /09, ..METHOD FOR THE DETECTION OF PRION PROTEINS/
PROTHERICS, EP-B 1 616 613 238
XXIV
IMAGE 7
CONTENTS
8.56 T 2278/09, ANALYTE CAPTURE DEVICE/ABBOTT, EP-A1 1 369 691 239
9 ENABLING DISCLOSURE: LEGAL BASIS, SUMMARY AND DISCUSSION OF THE EPO,
US AND JPO PRACTICE 240
9.1 ENABLING DISCLOSURE: EPO (ARTICLE 83 EPC) 240
9.2 ENABLING DISCLOSURE: US 250
9.3 ENABLING DISCLOSURE: JPO 265
10 ENABLING DISCLOSURE: THE EPO S CASE LAW 273
10.1 DECISIONS ON ENABLEMENT OF NUCLEIC ACID AND PROTEIN INVENTIONS 273
10.2 DECISIONS ON ENABLEMENT OF ANTIBODY TECHNOLOGY INVENTIONS 334
10.3 DECISIONS ON ENABLEMENT OF PLANT INVENTIONS 355
10.4 DECISIONS ON ENABLEMENT OF INVENTIONS CONCERNING VIRUSES AND THEIR
EPITOPES .. 363 10.5 DECISIONS ON ENABLEMENT OF INVENTIONS CONCERNING
MICROORGANISMS 380 10.6 DECISIONS ON ENABLEMENT OF OTHER INVENTIONS 391
11 DEPOSIT: LEGAL BASIS, SUMMARY AND DISCUSSION OF THE EPO, US AND JPO
PRACTICE 407
11.1 DEPOSIT: EPO (ARTICLE 83 EPC AND RULE 28 AND RULE 28A EPC1973/RULES
31 TO 34 EPC2000 OF THE IMPLEMENTING REGULATIONS) 407
11.2 DEPOSIT: US 412
11.3 DEPOSIT: JPO 415
12 DEPOSIT: THE EPO S CASE LAW 417
12.1 T 361/87, MICROORGANISMS/NABISCO, EP-A 97 973 417
12.2 T 39/88, MICROORGANISMS/CPC, EP-A 111 683 417
12.3 T 106/88, MICROORGANISMS/CPC, EP-A 112 459; T 90/88,
MICROORGANISM/ MICROLIFE, EP-A 76 953; T 239/87,
MICROORGANISMS/NABISCO , EP-A 98 533; T 142/93, ANTIBIOTICS/AMERICAN
CYANAMID, EP-A 182 152 418 12.4 T 118/87, AMYLOLYTIC ENZYMES/CPGS EP-A
34 470 418
12.5 J 8/87, J 9/87, SUBMITTING CULTURE DEPOSIT INFORMATION/IDAHO,
EP-A 155 476 418 12.6 EXAMINING DIVISION, DEPOSIT NUMBER/ROCKEFELLER,
EP 86 90 2639.3 . . 419 12.7 T 815/90, HEPATITIS-AVIRUS/UNITED STATES
OF AMERICA*, EP-A 196 316, G 2/93, ..SUFFICIENCY OF DISCLOSURE/CULTURE
DEPOSIT INFORMATION 419
12.8 T 886/91, ..HEPATITIS B VIRUS/BIOGEN, EP-B1 13 828 422
12.9 T 412/93, ERYTHROPOIETIN/AMGEN, EP-B1 148 605 422
12.10 T 923/92, T-PA/GENENTECH, EP-B1 63 619 423
12.11 T 128/92, INTERLEUKIN-2/AJINOMOTO, EP-B1 0 091 539 423
12.12 T 227/97, ..PROTEIN RIB/LINDAHL, EP-A 656 014 424
12.13 T 1147/01, PRRS VACCINE/AKZO NOBEL N.V.,EP-B1 610 250 424 12.14
T 328/04, ..HUMORAL IMMUNITY/DARTMOUTH COLLEGE-, EP-B1 742 721 424 12.15
QUESTIONS AND ANSWERS ADDRESSING SOME PRACTICAL PROBLEMS OF DEPOSITS FOR
EUROPEAN PATENT APPLICATIONS AND PCT APPLICATIONS DESIGNATING THE EPO .
. .. 425
13 PRIORITY: LEGAL BASIS, SUMMARY AND DISCUSSION OF THE EPO, US AND JPO
PRACTICE 430
13.1 PRIORITY: EPO (ARTICLES 87 TO 89 EPC) 430
13.2 PRIORITY: US 436
13.3 PRIORITY: JPO 446
XXV
IMAGE 8
CONTENTS
14 PRIORITY: THE EPO S CASE LAW 449
14.1 T 81/87, PREPRORENNIN/COLLABORATIVE, EP-A 57 350, OJ E PO 1990,
250 RO 259 449
14.2 T 269/87, PROCHYMOSIN/CELLTECH, EP-A 68 691 450
14.3 T 301/87, ALPHA-INTERFERONS/BIOGEN, EP-B 32 134, OJ E PO 1990,
335 TO 358 450
14.4 T 8 8 6 / 9 1, HEPARITIS B VIRUS/BIOGEN, EP-B1 13 828 450
14.5 T 2 9 6 / 9 3, HBVANTIGEN PRODUCTION/BLOGEN, EP-B1 182 442, O]
EPO 1995, 627 451
14.6 T 65/92, HTLV/HARVARD COLLEGE*, EP-A 151 579 452
14.7 T 207/94, FIBROBLAST INTERFERON/BIOGEN, EP-B1 41 313 453
14.8 T 4 4 1 / 9 3, CLONING IN KLUYVEROMYCES/GIST BROCADES, EP-B1 96
430 . . 454 14.9 T 413/94, ..HUMAN G M - C S F / I M M U N EX CORP.,
EP-B1 183 350 454
14.10 T 380/94, INSECT CONTROL/PGS, EP-B1 193 259 455
14.11 T 277/95 PRODUCTION OF ERYTHROPOIETIN/GENETICS INSTITUTE, EP-BI
411 678 456
14.12 T 2 3 6 / 9 6, INTERLEUKINL/DAINIPPON, EP-B1 188 920 457
14.13 T 9 1 9 / 9 3, HEAT TREATED FACTOR VIII/CEDARS-SINAI, EP-B 1 94
611 458
14.14 T 51/95, ..MATURE LEUKOCYTE INTERFERONS/HOFFMANN-LAROCHE, EP-B1
211 148 458
14.15 T 1112/96, ..ERYTHROPOIETIN PRODUCTION/GENETICS INSTITUTE*., EP-B1
205 564 458
14.16 T 542/95, TNF/YEDA, EP-B1 186 833 458
14.17 T 1147/98, ..CARTILAGE-INDUCING FACTOR/CELTRK PHARMACEUTICALS
INC., EP-B1 169 016 459
14.18 T 188/97, .NANBV/CHIRON CORPORATION*, EP-B1 318 216 460
14.19 T 479/97, EXPRESSION SYSTEM/NOVARTIS, EP-B1 353 188 460
14.20 T 351/98, HIV-I/CHIRON C O R P O R A T I O N *, EP-B1 181 150 461
14.21 T 342/98, A. ORIZAE/NOVOZYME, EP-B1 238 023 462
14.22 T 93/98, TNF INHIBITING PROTEIN/BASF, EP-B1 471 701 462
14.23 T 1099/99, ..FILAMENTOUS FUNGI/GENENCOR, EP-B1 215 594 464
14.24 T 216/96, ..PROCESS FOR AMPLIFYING, DETECTING AND/OR CLONING
NUCLEIC ACID SEQUENCES/F. H O F F M A N N - LA R O C HE AG, EP-B1 200
362 464
14.25 T 785/97, SUPPORT-BOUND OLIGONUCLEOTIDES/OXFORD GENE T E C H N O
L O GY L I M I T E D ., EP-B1 386 229 465
14.26 T 280/00, ..INHIBIN/GENENTECH, EP-BI 222 491 465
14.27 T 120/00, MYCOBACTERIA/COGENT, EP-BI 460 041 465
14.28 T 279/00, ..ASYMMETRIC REDUCTION PROCESS/AVECIA LTD., EP-BI 658
211 . . 466 14.29 T 356/00, ..MAMMARY GLAND FIX INTRON CONSTRUCT/PPL,
EP-BI 396 699 . . .. 466
14.30 T 552/00, . 3D-MPL/SMITHKLINE, EP-BI 689 454 467
14.31 T 1127/00, RIBOZYMES/GENE SHEARS, EP-BI 321 201 467
14.32 T 8 / 0 1, ..CHIMERIC CHAIN RECEPTORS/CELL GENESYS, EP-BI 517 895
468
14.33 T 351/01, ..TISSUE FACTOR PROTEIN/GENENTECH, EP-BI 278 776 468
14.34 T 4 2 3 / 0 1, LENGTH POLYMORPHISMS/MAX-PLANCK-GESELLSCHAFT,
EP-BI 438 512 469
14.35 T 4 8 6 / 0 1, . IGF-1/GENENTECH, INC., EP-BI 597 033 470
14.36 T 1014/01, RECOMBINANT IMMUNOCONJUGATES/BRISTOL-MYERS SQUIBB
CO. , EP-BI 439 095 470
14.37 T 1080/01, ..THERMOSTABLE ENZYME/F. H O F F M A N N - LA ROCHE,
EP-B 1 258 017 471
14.38 T 1074/00, ..HEMATOPOIETIC GROWTH FACTORS/GENETICS INSTITUTE*,
EP-BI 314 705 471
XXVI
IMAGE 9
CONTENTS
14.39 T 843/03, HUMAN PAPILLOMAVIRUS/THE UNIVERSITY OF ROCHESTER , EP-A
688 227 472
14.40 T 15/01, MYSTERY SWINE DISEASE/SDLO, EP-B1 587 780 472
14.41 T 20/04, FLT3 LIGANDS/SCHERING, EP-B1 699 236 474
14.42 T 464/94, .TRANSFORMATION OF PLANT GENETIC MATERIAL/NOVARTIS,
EP-B1 164 575 474
14.43 T 676/01, -TREATMENT OF INFLAMMATION/SONORAN DESERT CHEMICALS
LLC, EP-B1 512 090 474
14.44 T 1010/01, ACELLULAR VACCINE/MEDEVA B. V., EP-B1 471 726 475
14.45 T 293/04, LYME VACCINE/BAXTER, EP-B1 522 560 475
14.46 T 1127/03, WOUND HEALING/RENOVO, EP-B1 585 242 476
14.47 T 70/05, APOPTOSIS RECEPTORS/GENENTECH, EP-A1 904 366 476 14.48
T 1399/04, COMBINATION THERAPY HCV/SCHERING, EP-B1 956 861 477 14.49 T
562/04, FACTOR VLL/VON WILLEBRAND FACTOR COMPLEX/OCTAPHARMA, EP-B1 625
161 477
14.50 T 1190/03, .-ORPHAN RECEPTOR/KARO BIO, EP-B1 792 292 478 14.51 T
903/05, .TELEOMERASE PEPTIDES/GEMVAX, EP-B1 1 093 381 479 14.52 T
1147/02, ..ANTIBIOTIC RESISTANCE/PASTEUR; EP-B1 639 229 480 14.53 T
1213/05, ..BREAST AND OVARIAN CANCER/UNIVERSITY OF UTAH, EP-B1 705
902 480
14.54 T 250/06, OPIOID RECEPTOR GENES/UNIVERSITY OF CALIFORNIA, EP-B1
656 007 481
14.55 T 1380/05, ..PROTEIN STABILIZATION/NOVOZYMES, EP-B1 353 250 483
14.56 T 80/05, METHOD OF DIAGNOSIS/UNIVERSITY OF UTAH, EP-B1 699 754 .
483 14.57 T 666/05, MUTATION/UNIVERSITY OF UTAH, EP-B1 705 903 483
14.58 T 1127/06, BETA-AMYLOID PEPTIDE/ELAN, EP-B1 736 106 484 14.59 T
1338/06, ..MICROARRAY/LELAND STANFORT JUNIOR UNIVERSITY*,
EP-B1 804 731 485
14.60 T331/07, ..NEGATIVE-STRAND RNAVIRUS/CONZELMANN,EP-BL 702 085 ..
486 14.61 T 382/07, ETHERIC OILS/D&W TRADING, EP-BI 828 502 487
14.62 T 415/07, RIBOSOMAL DISPKY/DISCERNA LTD., EP-BI 985 032 488
14.63 T156/O8, ..BRCA2/UNIVERSITY OF UTAH,EP-AI 1260 520 488 14.64 T
1834/09, APO-2DCR/GENENTECH, EP-A1 1 032 661 489
14.65 T 146/07, ..PRENATAL DIAGNOSIS/ISIS, EP-BI 994 963 490
15 NOVELTY: LEGAL BASIS, SUMMARY AND DISCUSSION OF THE EPO, US AND JPO
PRACTICE 492
15.1 NOVELTY: EPO (ARTICLE 54 EPC/ARTIDE 54 EPC2000) . 492
15.2 NOVELTY: US 508
15.3 NOVELTY: JPO 521
16 NOVELTY: THE EPO S CASE LAW 528
16.1 DECISIONS ON NOVELTY FOR PROTEIN INVENTIONS 528
16.2 DECISIONS ON NOVELTY FOR D NA SEQUENCE INVENTIONS 560
16.3 DECISIONS ON NOVELTY OF INVENTIONS RELATING TO SYSTEMS FOR THE
EXPRESSION OF D NA SEQUENCES 575
16.4 DECISIONS ON NOVELTY FOR PLASMID INVENTIONS 588
16.5 DECISIONS ON NOVELTY FOR INVENTIONS ON ANTIBODY TECHNOLOGY 591
16.6 DECISIONS ON NOVELTY FOR PLANT AND ANIMAL RELATED INVENTIONS 604
16.7 VIRUSES AND THEIR EPITOPES 616
16.8 P CR AND OTHER IN VITRO NUCLEIC ACID AMPLIFICATION AND DETECTION
METHODS .. 630 16.9 MICROORGANISMS AND HOW TO MODIFY THEM 640
XXVII
IMAGE 10
CONTENTS
16.10 OTHER DECISIONS ON NOVELTY 649
17 INVENTIVE STEP: LEGAL BASIS, SUMMARY AND DISCUSSION OF THE EPO, US
AND JPO PRACTICE 682
17.1 INVENTIVE STEP: EPO (ARTICLE 56 EPC) 682
17.2 INVENTIVE STEP: US 694
17.3 INVENTIVE STEP: JPO 711
18 INVENTIVE STEP: THE EPO S CASE LAW 720
18.1 DECISIONS ON INVENTIVE STEP FOR PROTEIN INVENTIONS (INCLUDING
INVENTIONS RELATING TO METHODS FOR THE PREPARATION OF PROTEINS AND THEIR
USE) 720
18.2 DECISIONS ON INVENTIVE STEP FOR NUCLEIC ACID (SEQUENCE) INVENTIONS
774
18.3 DECISIONS ON INVENTIVE STEP OF INVENTIONS RELATING TO SYSTEMS FOR
THE EXPRESSION OF DNA SEQUENCES 833
18.4 DECISIONS ON INVENTIVE STEP FOR PLASMID INVENTIONS 864
18.5 DECISIONS ON INVENTIVE STEP FOR INVENTIONS ON ANTIBODY TECHNOLOGY
867
18.6 DECISIONS ON INVENTIVE STEP FOR PLANT AND ANIMAL RELATED INVENTIONS
897
18.7 VIRUSES AND THEIR EPITOPES 923
18.8 PCR AND OTHER IN VITRO NUCLEIC ACID AMPLIFICATION AND DETECTION
METHODS . . 958 18.9 MICROORGANISMS AND HOW TO MODIFY THEM 970
18.10 OTHER DECISIONS ON INVENTIVE STEP 984
19 DECISIONS OF THE EPO DEALING WITH PROCEDURAL ISSUES AND PROCEDURAL
CHANGES DUE TO EPC2000 1029
19.1 SUBSTANTIVE EXAMINATION: GENERAL 1029
19.2 OPPOSITION PROCEEDINGS: INTRODUCTION OF NEW GROUNDS 1041
19.3 OPPOSITION PROCEEDINGS: THE FILING OF NEW CLAIM REQUESTS 1045
19.4 OPPOSITION PROCEEDINGS: THE FILING OF NEW DOCUMENTS/EXPERIMENTAL
AND ODIER EVIDENCE AND DIE SUBMISSION OF NEW ARGUMENTS 1058
19.5 OPPOSITION PROCEEDINGS: ADAPTION OF DIE DESCRIPTION 1064
19.6 OPPOSITION PROCEEDINGS: THIRD PARTY INTERVENTION 1065
19.7 OPPOSITION PROCEEDINGS: STRAWMAN 1069
19.8 OPPOSITION PROCEEDINGS: SUBSTANTIAL PROCEDURAL VIOLATION AND
FAILURES IN THE OPPOSITION DIVISION S DECISION 1071
19.9 OPPOSITION AND APPEAL PROCEEDINGS: MISCELLANEOUS 1078
20 DRAFTING CLAIMS FOR A EUROPEAN PATENT APPLICATION 1100
21 EXAMPLES OF CLAIMS FOR A US PATENT APPLICATION 1102
21.1 INTRODUCTION 1102
21.2 CLAIMS RELATING TO CHEMICAL COMPOUNDS 1104
21.3 CLAIMS RELATING TO DNA SEQUENCES, VECTORS, PLASMIDS, HOST CELLS,
AND RECOMBINANT DNA MOLECULES 1105
21.4 EXAMPLES OF CLAIMS RELATING TO POLYPEPTIDES 1106
21.5 EXAMPLES OF CLAIMS RELATING TO MICROORGANISMS 1107
21.6 EXAMPLES OF CLAIMS RELATING TO MONOCLONAL ANTIBODIES 1108
21.7 EXAMPLES OF CLAIMS RELATING TO TRANSGENIC PLANTS AND ANIMALS 1109
21.8 METHOD OF TREATMENT CLAIMS 1111
21.9 CLAIMS THAT ARE NOT ALLOWABLE IN THE U. S. 1112
XXVIII
IMAGE 11
CONTENTS
22 EXAMPLES OF CLAIMS FOR A JAPANESE PATENT APPLICATION 1113
22.1 INTRODUCTION 1113
22.2 CLAIMS RELATING TO CHEMICAL COMPOUNDS 1114
22.3 CLAIMS RELATING TO DNA SEQUENCES 1115
22.4 CLAIMS RELATING TO RECOMBINANT PROTEINS 1116
22.5 CLAIMS RELATING TO VECTORS AND TRANSFORMANTS 1117
22.6 CLAIMS RELATING TO MICROORGANISMS 1117
22.7 CLAIMS RELATING TO MONOCLONAL ANTIBODIES 1118
22.8 CLAIMS RELATING TO TRANSGENIC PLANTS 1118
22.9 CLAIMS RELATING TO TRANSGENIC ANIMALS 1119
22.10 CLAIMS RELATING TO SCREENING METHODS 1119
22.11 CLAIMS RELATING TO ANTAGONISTS/INHIBITORS OR AGONISTS 1119
22.12 CLAIMS RELATING TO PHARMACEUTICAL INVENTIONS 1120
22.13 CLAIMS RELATING TO IPS 1121
23 HOW TO DRAFT THE DESCRIPTION OF A EUROPEAN PATENT APPLICATION IN
LIGHT OF EPC2000 AND THE CURRENT PRACTICE OF THE EPO 1122
23.1 THE TITLE OF THE INVENTION 1122
23.2 THE INDICATION OF THE FIELD OF THE INVENTION 1122
23.3 THE ACKNOWLEDGMENT OF THE PRIOR ART 1122
23.4 THE TECHNICAL PROBLEM UNDERLYING DIE INVENTION 1122
23.5 THE SOLUTION 1122
23.6 THE LEGENDS TO THE FIGURES 1125
23.7 EXAMPLES 1125
23.8 SEQUENCE LISTINGS 1125
23.9 THE ABSTRACT 1126
23.10 ONLINE FILING 1126
23.11 UNITY OF INVENTION AND DIVISIONAL APPLICATIONS 1127
23.12 FURTHER FORMAL ISSUES AND CHANGES DUE TO EPC2000 THAT HAVE TO BE
CONSIDERED WHEN DRAFTING PATENT APPLICATIONS 1130
24 HOW TO DRAFT THE DESCRIPTION OF A US PATENT APPLICATION 1133
24.1 THE ELEMENTS OF A U. S. PATENT APPLICATION 1133
24.2 MEETING THE REQUIREMENTS OF 35 U. S. C. § 112, FIRST PARAGRAPH 1138
25 HOW TO DRAFT THE DESCRIPTION OF A JAPANESE PATENT APPLICATION 1150
25.1 ELEMENTS OF A JAPANESE PATENT APPLICATION 1150
25.2 TITLE OF THE INVENTION 1150
25.3 TECHNICAL FIELD 1150
25.4 PRIOR ART 1150
25.5 PROBLEMS TO BE SOLVED BY THE INVENTION 1151
25.6 MEANS FOR SOLVING THE PROBLEMS 1151
25.7 EFFECTS OF THE INVENTION 1151
25.8 MODE FOR CARRYING OUT THE INVENTION 1152
25.9 EXAMPLES 1154
25.10 SEQUENCE LISTING 1155
25.11 ABSTRACT 1155
26 HOW TO KEEP NOTEBOOKS FOR SUCCESSFUL INTERFERENCES 1156
26.1 RECORD KEEPING TO ESTABLISH DATES OF INVENTION 1156
XXIX
IMAGE 12
CONTENTS
26.2 NOTEBOOKS 1157
26.3 ELECTRONIC AND OTHER RECORDS OF EXPERIMENTS 1159
27 EXTENSIONS TO PATENT TERM 1161
27.1 SUPPLEMENTARY PROTECTION CERTIFICATES (SPCS) FOR PHARMACEUTICALS
AND PLANT PROTECTION PRODUCTS IN EUROPE 1161
27.2 EXTENSIONS TO PATENT TERM IN THE US 1164
27.3 PATENT TERM EXTENSIONS: JPO 1167
DECISIONS OF THE EPO 1169
DECISIONS ON U. S. CASES 1205
DECISIONS ON JAPANESE CASES 1220
EUROPEAN STATUTES 1223
CROSS-REFERENCE LIST ARTICLE EPC1973 - ARTICLE/RULE EPC2000 1224
CROSS-REFERENCE LIST RULE EPC1973 - RULE EPC2000 1226
U. S. STATUTES 1231
JAPANESE STATUTES 1232
INDEX 1233
XXX
|
any_adam_object | 1 |
author_GND | (DE-588)1030592500 |
building | Verbundindex |
bvnumber | BV036724657 |
classification_rvk | PE 715 PS 3800 |
ctrlnum | (OCoLC)705908651 (DE-599)BVBBV036724657 |
discipline | Rechtswissenschaft |
edition | 5. ed. |
format | Book |
fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01655nam a2200385 c 4500</leader><controlfield tag="001">BV036724657</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20160217 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">101018s2012 |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783452274328</subfield><subfield code="9">978-3-452-27432-8</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)705908651</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV036724657</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-703</subfield><subfield code="a">DE-M382</subfield><subfield code="a">DE-19</subfield><subfield code="a">DE-12</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">PE 715</subfield><subfield code="0">(DE-625)135539:</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">PS 3800</subfield><subfield code="0">(DE-625)139790:</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">From clones to claims</subfield><subfield code="b">the European Patent Office's case law on the patentability of biotechnology inventions in comparison to the United States and Japanese practice</subfield><subfield code="c">by Hans-Rainer Jaenichen ...</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">5. ed.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Köln ; München [u.a.]</subfield><subfield code="b">Heymann</subfield><subfield code="c">2012</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XXX, 1240 S.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Heymanns intellectual property</subfield></datafield><datafield tag="610" ind1="2" ind2="7"><subfield code="a">Europäisches Patentamt</subfield><subfield code="0">(DE-588)1052705-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Biotechnologie</subfield><subfield code="0">(DE-588)4069491-4</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4152408-1</subfield><subfield code="a">Entscheidungssammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Europäisches Patentamt</subfield><subfield code="0">(DE-588)1052705-9</subfield><subfield code="D">b</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Biotechnologie</subfield><subfield code="0">(DE-588)4069491-4</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jaenichen, Hans-Rainer</subfield><subfield code="e">Sonstige</subfield><subfield code="0">(DE-588)1030592500</subfield><subfield code="4">oth</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">SWB Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=020642454&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-020642454</subfield></datafield></record></collection> |
genre | (DE-588)4152408-1 Entscheidungssammlung gnd-content |
genre_facet | Entscheidungssammlung |
id | DE-604.BV036724657 |
illustrated | Not Illustrated |
indexdate | 2024-07-09T22:46:39Z |
institution | BVB |
isbn | 9783452274328 |
language | English |
oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-020642454 |
oclc_num | 705908651 |
open_access_boolean | |
owner | DE-703 DE-M382 DE-19 DE-BY-UBM DE-12 |
owner_facet | DE-703 DE-M382 DE-19 DE-BY-UBM DE-12 |
physical | XXX, 1240 S. |
publishDate | 2012 |
publishDateSearch | 2012 |
publishDateSort | 2012 |
publisher | Heymann |
record_format | marc |
series2 | Heymanns intellectual property |
spelling | From clones to claims the European Patent Office's case law on the patentability of biotechnology inventions in comparison to the United States and Japanese practice by Hans-Rainer Jaenichen ... 5. ed. Köln ; München [u.a.] Heymann 2012 XXX, 1240 S. txt rdacontent n rdamedia nc rdacarrier Heymanns intellectual property Europäisches Patentamt (DE-588)1052705-9 gnd rswk-swf Biotechnologie (DE-588)4069491-4 gnd rswk-swf (DE-588)4152408-1 Entscheidungssammlung gnd-content Europäisches Patentamt (DE-588)1052705-9 b Biotechnologie (DE-588)4069491-4 s DE-604 Jaenichen, Hans-Rainer Sonstige (DE-588)1030592500 oth SWB Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=020642454&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
spellingShingle | From clones to claims the European Patent Office's case law on the patentability of biotechnology inventions in comparison to the United States and Japanese practice Europäisches Patentamt (DE-588)1052705-9 gnd Biotechnologie (DE-588)4069491-4 gnd |
subject_GND | (DE-588)1052705-9 (DE-588)4069491-4 (DE-588)4152408-1 |
title | From clones to claims the European Patent Office's case law on the patentability of biotechnology inventions in comparison to the United States and Japanese practice |
title_auth | From clones to claims the European Patent Office's case law on the patentability of biotechnology inventions in comparison to the United States and Japanese practice |
title_exact_search | From clones to claims the European Patent Office's case law on the patentability of biotechnology inventions in comparison to the United States and Japanese practice |
title_full | From clones to claims the European Patent Office's case law on the patentability of biotechnology inventions in comparison to the United States and Japanese practice by Hans-Rainer Jaenichen ... |
title_fullStr | From clones to claims the European Patent Office's case law on the patentability of biotechnology inventions in comparison to the United States and Japanese practice by Hans-Rainer Jaenichen ... |
title_full_unstemmed | From clones to claims the European Patent Office's case law on the patentability of biotechnology inventions in comparison to the United States and Japanese practice by Hans-Rainer Jaenichen ... |
title_short | From clones to claims |
title_sort | from clones to claims the european patent office s case law on the patentability of biotechnology inventions in comparison to the united states and japanese practice |
title_sub | the European Patent Office's case law on the patentability of biotechnology inventions in comparison to the United States and Japanese practice |
topic | Europäisches Patentamt (DE-588)1052705-9 gnd Biotechnologie (DE-588)4069491-4 gnd |
topic_facet | Europäisches Patentamt Biotechnologie Entscheidungssammlung |
url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=020642454&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
work_keys_str_mv | AT jaenichenhansrainer fromclonestoclaimstheeuropeanpatentofficescaselawonthepatentabilityofbiotechnologyinventionsincomparisontotheunitedstatesandjapanesepractice |